Menopause and weight: what actually changes

This needs stating before anything else, because a great many people have been told otherwise by someone who should have known better.

The NHS lists weight gain among the symptoms of perimenopause and menopause, and describes where it goes: "Weight gain during perimenopause and menopause is common. It often happens around the stomach and upper body." That is not a lifestyle observation attached to a hormonal condition. It is listed as a symptom, in the same list as hot flushes, sleep problems, muscle aches and joint pains, and bone thinning.

So if the experience has been that the same eating and the same activity stopped producing the same result somewhere in your forties, the explanation is not that you quietly became less disciplined at forty-three. Something changed, and it is documented.

The most important thing about menopausal weight change is that it is a change in *where* fat sits as much as how much there is — and the scale cannot see that at all.

Oestrogen influences fat distribution. While it is high, storage is biased toward the hips and thighs; as it falls, that bias shifts toward the abdomen, including the visceral fat packed around the organs rather than the subcutaneous fat under the skin. The NHS describes the same pattern from the outside: around the stomach and upper body.

Those two kinds of fat are not equivalent. Visceral fat is the one associated with insulin resistance, with raised blood pressure and with cardiovascular risk. Which means someone can be weighed, told the number is acceptable, and sent away while the change that actually carries risk proceeds unmeasured.

The practical consequence is a different instrument. A tape measure around the waist, taken a few times a year, tells you more about this particular transition than the scale does. It is also the measurement most likely to show improvement first when something is working, which is worth knowing when the scale is being discouraging.

Muscle mass declines with age in everybody. Around menopause it declines faster, and oestrogen appears to be part of why — muscle tissue carries oestrogen receptors, and the hormone is involved in maintaining it.

This matters arithmetically rather than cosmetically. Muscle is metabolically active tissue; losing it lowers the energy your body uses at rest. So the intake that held your weight steady at thirty-eight is genuinely a surplus at fifty, without anything about your behaviour having changed. The equation moved, not your willpower.

It also means resistance training stops being optional at precisely the point most people stop doing it. Of everything in this post, that is the intervention with the best return: it is the only one that addresses the muscle side directly, it protects bone at a stage when bone thinning is also on the NHS symptom list, and its benefits do not depend on losing any weight at all.

Sleep problems are on the NHS list too, and they are easy to file as merely unpleasant. They are not merely unpleasant: short and broken sleep raises appetite, shifts food preference toward energy-dense choices, and reduces the capacity to execute any plan you made while rested.

Night sweats and the wakings that follow them are therefore not only a symptom to be endured in parallel with a weight problem. They are part of the mechanism, and treating them is a legitimate part of addressing the weight — which is a reason to raise sleep with a clinician rather than treating it as the thing you mention last if there is time.

HRT is an effective treatment for menopausal symptoms and the NHS sets out what it is for: oestrogen as the main component, with progestogen alongside it where the womb is intact, and local preparations for vaginal and urinary symptoms.

What the NHS page describing HRT does not list is weight. It is not a weight-loss treatment, it is not sold as one by the health service, and a good deal of what is marketed around it says otherwise. If better-managed symptoms mean better sleep and more capacity to be active, that can help indirectly — but that is a different claim from the one being made in most advertising, and worth separating.

The honest framing: treat the symptoms because the symptoms are worth treating. Judge the weight separately, on its own evidence.

As with every condition in this series, this is where most writing turns into marketing, so it is worth being exact.

No GLP-1 medicine is licensed to treat menopause or menopausal weight gain. Not Mounjaro, not Wegovy, not the tablets. Menopause is not an indication and nobody should tell you it is.

What is accurate is narrower. These medicines are licensed for weight management in adults with a BMI of 30 or above, or 27 to under 30 **in the presence of at least one weight-related comorbidity**. The licences name what counts: dysglycaemia — prediabetes or type 2 diabetes — along with hypertension, dyslipidaemia and obstructive sleep apnoea.

Menopause itself is not on that list. But every condition on it becomes more common across this transition, and the visceral redistribution described above is precisely the kind that drives them. So the question that decides eligibility between a BMI of 27 and 30 is not whether you are menopausal; it is whether your blood pressure, lipids and glucose have been measured recently enough to know where you stand.

If they have not been, that is the thing to ask for, and it is useful whatever you decide about treatment.